{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"LFWD","limit":50},"count":50,"signals":[{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":13,"context":", or to comply with applicable regulatory requirements, could result in enforcement actions, injunctions, civil or criminal penalties, and may materially adversely affect our ability to commercialize AI-enabled products and our financial condition and results of operations. The rapid evolution of artificial intelligence will require the application of significant resources to design, develop, test and maintain such","filed_date":"2026-03-18","accession":"0001178913-26-001208","full_text":"https://origin.rootz.global/static/filing/0001178913-26-001208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":96,"context":"pertaining to marketing and promotional communications, among others. Failure to comply with such regulations may give rise to a number of potential FDA enforcement actions, any of which could have a material adverse effect on our business. | | |  |  We are not able to protect our intellectual property rights in all countries. | | |  |  If we are unable to offer our key management personnel long-term incentive compensat","filed_date":"2026-03-18","accession":"0001178913-26-001208","full_text":"https://origin.rootz.global/static/filing/0001178913-26-001208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":39,"context":"n AbilityLab to expand evaluation and access opportunities for the ReWalk Personal Exoskeleton for individuals with spinal cord injuries in the United States. | | |  |  | | |  |  In February 2026, we entered into a definitive agreement to acquire certain technology assets and related intellectual property from Skelable Ltd. relating to a powered upper-extremity orthotic device under development. The consideration for the transactio","filed_date":"2026-03-18","accession":"0001178913-26-001208","full_text":"https://origin.rootz.global/static/filing/0001178913-26-001208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":50,"context":"nditions Precedent to Obligations of Parent. |  |  | |  9.1 |  Accuracy of Representations |  63 |  | |  9.2 |  Performance of Covenants |  64 |  | |  9.3 |  Documents |  64 |  | |  9.4 |  No Company Material Adverse Effect |  64 |  | |  9.5 |  Company Stockholder Written Consent |  64 |  | |  9.6 |  Company Minimum Cash |  64 |  | |  9.7 |  Parent Financing |  64 |  | |  9.8 |  Lock-Up Agreement. |  64 |  | |  9.9 |  C","filed_date":"2026-01-13","accession":"0001178913-26-000132","full_text":"https://origin.rootz.global/static/filing/0001178913-26-000132.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":28,"context":"Agreements means, collectively, the Lock-Up Agreements, dated as of the date hereof, by and among the Company and the directors and officers of the Company, in the form of Exhibit C attached hereto. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Ordinary Shares means the ordinary shares of the Compa","filed_date":"2025-06-26","accession":"0001178913-25-002251","full_text":"https://origin.rootz.global/static/filing/0001178913-25-002251.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":45,"context":"Majority. |  Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote. |  Yes. |  | |  Proposal 8: Approval, on an advisory basis, of the compensation of the Companys named executive officers. |  Affirmative vote of an Ordinary Majority. |  Abstentions and broker non-votes will have no effect on the outcome of the vote. |  No. |  | Special Majority Under Israeli law, Proposal 2 requires,","filed_date":"2025-06-26","accession":"0001178913-25-002243","full_text":"https://origin.rootz.global/static/filing/0001178913-25-002243.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":24,"context":"shall have the meaning ascribed to such term in Section 3(mm). Liens shall have the meaning ascribed to such term in Section 3(a). Losses shall have the meaning ascribed to such term in Section 7(d). Material Adverse Effect shall have the meaning ascribed to such term in Section 3(b). Material Permits shall have the meaning ascribed to such term in Section 3(t). Maximum Amount shall have the meaning ascribed to such ter","filed_date":"2025-03-07","accession":"0001178913-25-000742","full_text":"https://origin.rootz.global/static/filing/0001178913-25-000742.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":91,"context":"pertaining to marketing and promotional communications, among others. Failure to comply with such regulations may give rise to a number of potential FDA enforcement actions, any of which could have a material adverse effect on our business. | | | | | We are not able to protect our intellectual property rights in all countries. | | | | | If we are unable to offer our key management personnel long-term incentive compensat","filed_date":"2025-03-07","accession":"0001178913-25-000736","full_text":"https://origin.rootz.global/static/filing/0001178913-25-000736.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":33,"context":"part of the year ended December 31, 2024, and (2) our two most highly compensated executive officers (other than our CEO) who were serving as executive officers as of December 31, 2024 (together, our Named Executive Officers). Named Executive Officers Our Named Executive Officers for the year ended December 31, 2024, which consists of our principal executive officer and our two other most highly compensated executive of","filed_date":"2025-03-07","accession":"0001178913-25-000736","full_text":"https://origin.rootz.global/static/filing/0001178913-25-000736.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":25,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Ordinary Shares means the ordinary shares of the Compa","filed_date":"2025-01-08","accession":"0001178913-25-000065","full_text":"https://origin.rootz.global/static/filing/0001178913-25-000065.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":47,"context":"nary Majority. | Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote. | Yes. | | | Proposal 9: Approval, on an advisory basis, of the compensation of the Companys named executive officers. | Affirmative vote of an Ordinary Majority. | Abstentions and broker non-votes will have no effect on the outcome of the vote. | No. | | 5 Special Majority Under Israeli law, each of Proposals 5 an","filed_date":"2024-07-29","accession":"0001178913-24-002344","full_text":"https://origin.rootz.global/static/filing/0001178913-24-002344.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":34,"context":"part of the year ended December 31, 2023, and (2) our two most highly compensated executive officers (other than our CEO) who were serving as executive officers as of December 31, 2023 (together, our Named Executive Officers). Named Executive Officers Our Named Executive Officers for the year ended December 31, 2023, which consists of our principal executive officer and our two other most highly compensated executive of","filed_date":"2024-04-29","accession":"0001178913-24-001464","full_text":"https://origin.rootz.global/static/filing/0001178913-24-001464.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":76,"context":"facility registration, reporting of adverse events and labeling. Failure to comply with the general and special controls could lead to removal of ReStore or ReWalk from the market, which would have a material adverse effect on our business. In June 2022, we submitted a 510(k) premarket notification for ReWalk Personal Exoskeleton seeking to enable the stairs functionality and add uses on stairs and curbs to the indicati","filed_date":"2024-02-27","accession":"0001178913-24-000730","full_text":"https://origin.rootz.global/static/filing/0001178913-24-000730.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":8,"context":"grow our business through acquisitions of businesses, products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, which could have a material adverse effect on our business, financial condition, and operating results; | | |  |  our expectations as to our clinical research program and clinical results; | | |  |  our ability to obtain certain components of","filed_date":"2023-11-14","accession":"0001178913-23-003671","full_text":"https://origin.rootz.global/static/filing/0001178913-23-003671.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":35,"context":"Majority. |  Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote. |  Yes. |  | |  Proposal 8: Approval, on an advisory basis, of the compensation of the Companys named executive officers. |  Affirmative vote of an Ordinary Majority. |  Abstentions and broker non-votes will have no effect on the outcome of the vote. |  No. |  | 5 Special Majority Under Israeli law, each of Proposal 2","filed_date":"2023-08-09","accession":"0001178913-23-002786","full_text":"https://origin.rootz.global/static/filing/0001178913-23-002786.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ark, logo and design mark, trade dress, trade name, fictitious or other business name, and brand name, together with all goodwill, registrations and applications associated with any of the foregoing. Material Adverse Effect when used in connection with an entity means any effect, event, change, fact, occurrence, circumstance or development, that individually or in the aggregate has had or would reasonably be expected to","filed_date":"2023-08-09","accession":"0001178913-23-002776","full_text":"https://origin.rootz.global/static/filing/0001178913-23-002776.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":44,"context":"grow our business through acquisitions of businesses, products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, which could have a material adverse effect on our business, financial condition, and operating results; | | |  |  our expectations as to our clinical research program and clinical results; | | |  |  our ability to obtain certain components of","filed_date":"2023-02-23","accession":"0001178913-23-000722","full_text":"https://origin.rootz.global/static/filing/0001178913-23-000722.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"C Topic 718). The fair value of RSUs granted is determined based on the price of the Companys ordinary shares on the date of grant. All RSUs become vested and exercisable in four equal quarterly installments starting three months following the grant date. The valuation assumptions used in determining such amounts are described in Notes 2k and 8c to our consolidated financial statements included in ou","filed_date":"2022-06-23","accession":"0001178913-22-002469","full_text":"https://origin.rootz.global/static/filing/0001178913-22-002469.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":29,"context":"votes for Proposal 5, and abstentions will not be treated as either a vote FOR or AGAINST the proposal. |  Yes. |  | |  Proposal 6: Approval, on an advisory basis, of the compensation of the Companys named executive officers. |  Affirmative vote of an Ordinary Majority. |  Abstentions and broker non-votes will not be treated as either a vote FOR or AGAINST the proposal. |  No. |  | |  Proposals 7.a. and 7.b.: Shareholde","filed_date":"2022-06-23","accession":"0001178913-22-002469","full_text":"https://origin.rootz.global/static/filing/0001178913-22-002469.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":44,"context":"grow our business through acquisitions of businesses, products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, which could have a material adverse effect on our business, financial condition, and operating results; | | |  |  our expectations as to our clinical research program and clinical results; | | |  |  our ability to obtain certain components of","filed_date":"2022-02-24","accession":"0001178913-22-000800","full_text":"https://origin.rootz.global/static/filing/0001178913-22-000800.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":23,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Ordinary Shares means the ordinary shares of the Compa","filed_date":"2021-09-29","accession":"0001178913-21-003062","full_text":"https://origin.rootz.global/static/filing/0001178913-21-003062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":19,"context":"in 2023. Except as indicated herein, there are no arrangements or understandings between any director or nominee for directorship and any other person pursuant to which such director or nominee was selected as director or nominee. Upon recommendation of our nominating and corporate governance committee, our Board has nominated Messers. Jeff Dykan and Mr. Yasushi Ichiki as Class I directors to serve until the 2024 a","filed_date":"2021-04-12","accession":"0001178913-21-001331","full_text":"https://origin.rootz.global/static/filing/0001178913-21-001331.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":23,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). 3 Ordinary Shares means the ordinary shares of the Com","filed_date":"2021-02-25","accession":"0001178913-21-000792","full_text":"https://origin.rootz.global/static/filing/0001178913-21-000792.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"bilities, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. Under the Collaboration Agreement, we pay Harvard quarterly installment payments to help fund the research. Subject to the terms of the Collaboration Agreement, we and Harvard are required to report our respective research results and findings to each other on a regul","filed_date":"2021-02-18","accession":"0001178913-21-000678","full_text":"https://origin.rootz.global/static/filing/0001178913-21-000678.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":40,"context":"events and labeling, and the special controls established for the device. Failure to comply with the general and special controls could lead to removal of ReStore from the market, which would have a material adverse effect on our business. For more information, see Part I, Item 1A. Risk Factors-Risks Related to Government Regulation-We are subject to extensive governmental regulations relating to the manufacturing, lab","filed_date":"2021-02-18","accession":"0001178913-21-000678","full_text":"https://origin.rootz.global/static/filing/0001178913-21-000678.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":23,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). 3 Certain confidential information contained in this d","filed_date":"2020-12-08","accession":"0001178913-20-003336","full_text":"https://origin.rootz.global/static/filing/0001178913-20-003336.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":23,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). 3 Ordinary Shares means the ordinary shares of the Com","filed_date":"2020-07-06","accession":"0001178913-20-001968","full_text":"https://origin.rootz.global/static/filing/0001178913-20-001968.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":30,"context":"| |  |  5. |  To approve, on an advisory basis, the Companys executive compensation, commonly referred to as a say-on-payvote. |  | |  |  6. |  To approve, on an advisory basis, the frequency of the named executive officer compensation advisory vote. |  | |  |  7. |  To approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Companys independent registered public accounting f","filed_date":"2020-05-12","accession":"0001178913-20-001441","full_text":"https://origin.rootz.global/static/filing/0001178913-20-001441.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"ies, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. Under the Collaboration Agreement, we must pay Harvard quarterly installment payments to help fund the research. Subject to the terms of the Collaboration Agreement, we and Harvard are required to report our respective research results and findings to each other on a regul","filed_date":"2020-02-20","accession":"0001213900-20-004363","full_text":"https://origin.rootz.global/static/filing/0001213900-20-004363.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":42,"context":"events and labeling, and the special controls established for the device. Failure to comply with the general and special controls could lead to removal of ReStore from the market, which would have a material adverse effect on our business. For more information, see Part I, Item 1A. Risk Factors-Risks Related to Government Regulation-We are subject to extensive governmental regulations relating to the manufacturing, lab","filed_date":"2020-02-20","accession":"0001213900-20-004363","full_text":"https://origin.rootz.global/static/filing/0001213900-20-004363.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (FASB ASC Topic 718). All RSUs become vested and exercisable in four equal quarterly installments starting three months following the grant date. The valuation assumptions used in determining such amounts are described in Notes 2k and 8c to our consolidated financial statements included in ou","filed_date":"2019-02-19","accession":"0001213900-19-002860","full_text":"https://origin.rootz.global/static/filing/0001213900-19-002860.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":17,"context":"cable to smaller reporting companies. In addition, as an emerging growth company, we are not required to conduct votes seeking shareholder approval on an advisory basis of (1) the compensation of our named executive officers or the frequency with which such votes must be conducted or (2) compensation arrangements and understandings in connection with merger transactions, known as golden parachute arrangements. Under the","filed_date":"2019-02-19","accession":"0001213900-19-002860","full_text":"https://origin.rootz.global/static/filing/0001213900-19-002860.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ture Products. For more information on the collaboration with Harvard, see Research and Development-Research and Development Collaborations. ** ** 2 ** ** **Recent Developments** |  | | Completed enrollment in the clinical study of the ReStore soft exo-suit for stroke patients: | | |  | o | On track to file a 510k submission with the U.S. Food and Drug Administration (FDA) imminently; | | |  | | Appl","filed_date":"2019-02-08","accession":"0001213900-19-001871","full_text":"https://origin.rootz.global/static/filing/0001213900-19-001871.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":34,"context":"(k) cleared device or withdrawing PMA approval; | | |  | | refusal to grant export approvals for our products; or | | |  | | pursuing criminal prosecution. | | Any such action by the FDA would have a material adverse effect on our business. In addition, these regulatory controls, as well as any changes in FDA policies, can affect the time and cost associated with the development, introduction and continued availability","filed_date":"2019-02-08","accession":"0001213900-19-001871","full_text":"https://origin.rootz.global/static/filing/0001213900-19-001871.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":20,"context":"cable to smaller reporting companies. In addition, as an emerging growth company, we are not required to conduct votes seeking shareholder approval on an advisory basis of (1) the compensation of our named executive officers or the frequency with which such votes must be conducted or (2) compensation arrangements and understandings in connection with merger transactions, known as golden parachute arrangements. Under the","filed_date":"2018-03-26","accession":"0001213900-18-003438","full_text":"https://origin.rootz.global/static/filing/0001213900-18-003438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"CLOSING** ** ** 4.1 Conditions to the Obligations of the Company and the Investor. The respective obligations of the Company and the Investor hereunder to consummate each Closing are subject to fulfillment, prior to or at each Closing, of the following conditions (compliance with which or the occurrence of which may be waived in whole or in part by either the Company or the Investor in writing with","filed_date":"2018-03-23","accession":"0001213900-18-003384","full_text":"https://origin.rootz.global/static/filing/0001213900-18-003384.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":24,"context":"n. (b) The Company and each of its subsidiaries has the full corporate power and authority to own its properties and conduct its business as currently conducted, and, except as would not constitute a Material Adverse Effect, has been and is duly qualified as a foreign corporation for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties, or co","filed_date":"2018-03-23","accession":"0001213900-18-003384","full_text":"https://origin.rootz.global/static/filing/0001213900-18-003384.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":31,"context":"d device or withdrawing PMA approval; | | | | | | | | refusal to grant export approvals for our products; or | | | | | | | | pursuing criminal prosecution. | | Any such action by the FDA would have a material adverse effect on our business. In addition, these regulatory controls, as well as any changes in FDA policies, can affect the time and cost associated with the development, introduction and continued availability","filed_date":"2018-03-08","accession":"0001607962-18-000007","full_text":"https://origin.rootz.global/static/filing/0001607962-18-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":19,"context":"closure permitted under the JOBS Act. In addition, as an emerging growth company, we are not required to conduct votes seeking shareholder approval on an advisory basis of (1) the compensation of our named executive officers or the frequency with which such votes must be conducted or (2) compensation arrangements and understandings in connection with merger transactions, known as golden parachute arrangements. Under the","filed_date":"2017-05-22","accession":"0001178913-17-001564","full_text":"https://origin.rootz.global/static/filing/0001178913-17-001564.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":28,"context":"d device or withdrawing PMA approval; | | | | | | | | refusal to grant export approvals for our products; or | | | | | | | | pursuing criminal prosecution. | | Any such action by the FDA would have a material adverse effect on our business. In addition, these regulatory controls, as well as any changes in FDA policies, can affect the time and cost associated with the development, introduction and continued availability","filed_date":"2017-02-17","accession":"0001607962-17-000006","full_text":"https://origin.rootz.global/static/filing/0001607962-17-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":16,"context":"reputation. If we are unable to expand our sales, marketing and training capabilities, we may not be able to effectively commercialize ReWalk, or enhance the strength of our brand, which could have a material adverse effect on our operating results. The health benefits of ReWalk have not been substantiated by long-term clinical data, which could limit sales. Although our interim analysis of an ongoing study demonstrates","filed_date":"2016-11-03","accession":"0001607962-16-000022","full_text":"https://origin.rootz.global/static/filing/0001607962-16-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":24,"context":"of property or the conduct of its businesses requires such qualification, except where the failure to be so qualified or in good standing would not, in the aggregate, reasonably be expected to have a material adverse effect on the condition (financial or otherwise), results of operations, shareholders equity, properties, business or prospects of the Company and its subsidiaries taken as a whole (a **Material Adverse Eff","filed_date":"2016-05-10","accession":"0001144204-16-100138","full_text":"https://origin.rootz.global/static/filing/0001144204-16-100138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":16,"context":"closure permitted under the JOBS Act. In addition, as an emerging growth company, we are not required to conduct votes seeking shareholder approval on an advisory basis of (1) the compensation of our named executive officers or the frequency with which such votes must be conducted or (2) compensation arrangements and understandings in connection with merger transactions, known as golden parachute arrangements. Under the","filed_date":"2016-04-07","accession":"0001178913-16-005004","full_text":"https://origin.rootz.global/static/filing/0001178913-16-005004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":20,"context":"pprovals of new products or modified products; | | | | | | | | refusal to grant export approvals for our products; or | | | | | | | | criminal prosecution. | | Any such action by the FDA would have a material adverse effect on our business. In addition, these regulatory controls, as well as any changes in FDA policies, can affect the time and cost associated with the development, introduction and continued availability","filed_date":"2016-02-29","accession":"0001607962-16-000007","full_text":"https://origin.rootz.global/static/filing/0001607962-16-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":20,"context":"reputation. If we are unable to expand our sales, marketing and training capabilities, we may not be able to effectively commercialize ReWalk, or enhance the strength of our brand, which could have a material adverse effect on our operating results. The health benefits of ReWalk have not been substantiated by long-term clinical data, which could limit sales. Although our interim analysis of an ongoing study demonstrates","filed_date":"2015-02-27","accession":"0001178913-15-000744","full_text":"https://origin.rootz.global/static/filing/0001178913-15-000744.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"mputed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (FASB ASC Topic 718). All options become vested and exercisable in four equal quarterly installments starting three months following the grant date. The valuation assumptions used in determining such amounts are described in Notes 2k and 8c to our consolidated financial statements included in ou","filed_date":"2018-03-26","accession":"0001213900-18-003438","full_text":"https://origin.rootz.global/static/filing/0001213900-18-003438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"SC Topic 718. The fair value of RSUs granted is determined based on the price of the Companys ordinary shares on the date of grant. All RSUs become vested and exercisable in four equal quarterly installments starting three months following the grant date. The valuation assumptions used in determining such amounts are described in Notes 2k and 8c to our consolidated financial statements included in ou","filed_date":"2021-04-12","accession":"0001178913-21-001331","full_text":"https://origin.rootz.global/static/filing/0001178913-21-001331.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"nt in Italy. | | | | | | | | Five top rehabilitation centers in the United States. received institutional review board approval for ReWalks Restore clinical study in stroke patients, with patient enrollment planned to begin in the first quarter of 2018. | | | | | | | | Gross margin increased to 40% in 2017 as compared to 13% in 2016. | | | | | | | | On March 6, 2018, we entered into an investment agr","filed_date":"2018-03-08","accession":"0001607962-18-000007","full_text":"https://origin.rootz.global/static/filing/0001607962-18-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":88,"match_count":11,"context":"xecutive Officer is appointed by, and serves at the discretion of our board of directors, subject to the employment agreement that we have entered into with him. All other executive officers are also appointed by our board of directors, and are subject to the terms of any applicable employment agreements that we may enter into with them. We comply with the NASDAQ rules that require a majority of our directors be independent. Our b","filed_date":"2015-02-27","accession":"0001178913-15-000744","full_text":"https://origin.rootz.global/static/filing/0001178913-15-000744.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LFWD","company":"Lifeward Ltd.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"on April 1, 2018 (as amended, the &#x201C;License Agreement&#x201D;), to extend the term of the Collaboration Agreement by one year to May 16, 2022 and reallocate the Company&#x2019;s quarterly installment payments to Harvard through such date, and to make certain technical changes. On April 30, 2020, the Company and Harvard amended the Collaboration Agreement, which included certain adjustments to","filed_date":"2021-11-10","accession":"0001178913-21-003473","full_text":"https://origin.rootz.global/static/filing/0001178913-21-003473.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"773370b41f639dad71c4241a6dd06eefd289a087afdf39d9a152e0528c3e7057","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"e1f6c88bdd2ccf8fcad21c713645f514010ff61faa43d420b237fdd51cb435a7","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":108,"hourly_limit":500,"remaining":392,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}